S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
The 3-Stock Retirement Blueprint (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
The 3-Stock Retirement Blueprint (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
The 3-Stock Retirement Blueprint (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
The 3-Stock Retirement Blueprint (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
The 3-Stock Retirement Blueprint (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
The 3-Stock Retirement Blueprint (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
The 3-Stock Retirement Blueprint (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
The 3-Stock Retirement Blueprint (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
ETR:MOR

MorphoSys - MOR Price Target & Analyst Ratings

€20.56
-1.09 (-5.03%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
€20.36
€22.08
50-Day Range
€16.54
€24.03
52-Week Range
€16.08
€43.29
Volume
248,097 shs
Average Volume
153,687 shs
Market Capitalization
$702.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
€43.92

MorphoSys Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

N/A
Based on 0 Analyst Ratings

Consensus Analyst Price Target

€43.92
High Prediction€76.00
Average Prediction€43.92
Low Prediction€24.00
TypeCurrent
10/2/21 to 10/2/22
1 Month Ago
9/2/21 to 9/2/22
3 Months Ago
7/4/21 to 7/4/22
1 Year Ago
10/2/20 to 10/2/21
Consensus RatingN/AN/AN/A
Moderate Buy
Strong Buy N/A N/A N/A
0 Strong Buy rating(s)
Buy N/A N/A N/A
4 Buy rating(s)
Hold N/A N/A N/A
4 Hold rating(s)
Sell N/A N/A N/A
0 Sell rating(s)
Consensus Price Target€43.92€43.92€51.71€78.89
Get MorphoSys Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter.


MOR Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MOR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

MorphoSys Stock vs. The Competition

TypeMorphoSysMedical Companies
Consensus Rating Score
0.00
2.68
Consensus RatingN/ABuy
News Sentiment RatingNeutral News
Positive News
MarketBeat
Community Rating
Outperform Votes
333
64.79%
Underperform Votes
181
35.21%
Avg. Outperform Votes
166
66.67%
Avg. Underperform Votes
83
33.33%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/28/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
James Gordon
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target€32.50+75.68%
8/4/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Keyur Parekh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target€24.00+5.22%
8/4/2022Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Xian Deng
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target€65.00+184.96%
7/27/2022Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Emmanuel Papadakis
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target€30.00+37.30%
3/17/2022Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Brian, Balchin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target€36.00+50.38%
11/12/2021Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
James, Quigley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target€76.00+103.26%
7/5/2021Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Set Target€97.00+51.23%
3/17/2021Independent Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Set TargetBuy€95.00+26.63%
3/16/2021Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Set TargetNeutral€130.00+54.91%
5/12/2020HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Set TargetNeutral€114.00-5.12%
(Data available from 10/2/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












MOR Price Target - Frequently Asked Questions

Do MarketBeat users like MorphoSys more than its competitors?

MarketBeat users like MorphoSys less than other Medical companies. 64.79% of MarketBeat users gave MorphoSys an outperform vote while medical companies recieve an average of 66.53% outperform votes by MarketBeat users.

Does MorphoSys's stock price have much upside?

According to analysts, MorphoSys's stock has a predicted upside of 78.89% based on their 12-month price targets.

What analysts cover MorphoSys?

MorphoSys has been rated by Berenberg Bank, Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., and The Goldman Sachs Group in the past 90 days.


Stock Ratings Reports and Tools

This page (ETR:MOR) was last updated on 10/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.